Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies.
Retired greyhound dogs, with low or absent antibody titers to rabies virus following previous vaccinations with commercially available vaccines, were immunized either subcutaneously or intramuscularly with a replication-defective recombinant adenovirus expressing the rabies virus glycoprotein termed Adrab.gp. Immunized animals developed high titers (geometric mean titers of 2630 and 5329) of viral neutralizing antibodies (VNA) against rabies virus by 10 days after vaccination. The antibody titers were even higher (geometric mean titers of 19349 and 122086) by 21 days after vaccination. The results indicate that the recombinant adenovirus expressing rabies virus glycoprotein is capable of inducing antibody immune responses in dogs and therefore may be developed as a rabies virus vaccine for dogs.
Tims
T
T
Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan 66506, USA.
Briggs
D J
DJ
Davis
R D
RD
Moore
S M
SM
Xiang
Z
Z
Ertl
H C
HC
Fu
Z F
ZF
D000260:Adenoviruses, Human / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D004274:DNA, Recombinant / Q000235:genetics / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology* / Q000821:virology; D004285:Dogs; D007117:Immunization, Secondary / Q000662:veterinary*; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D009500:Neutralization Tests; D011818:Rabies / Q000276:immunology* / Q000662:veterinary; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D011820:Rabies virus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology
D000914:Antibodies, Viral; D004274:DNA, Recombinant; D011819:Rabies Vaccines; D014614:Vaccines, Synthetic; D014764:Viral Proteins; C079096:adenovirus 5, rabies glycoprotein recombinant vaccine